Month: May 2023

Table 1 FDA Required Primary Efficacy EndpointFigure 2 Study BDX-22-006 Primary EndpointFigure 3 Study BDX-22-006Announced Positive Top-Line Final Results from Phase 2 Randomized Clinical Trial of BX1000 Hosted Key Opinion Leader Webinar to Highlight Potential of BX1000 and Neuromuscular Blocking Agent Portfolio Secured $4 Million in Gross Proceeds from Public Offering in May MALVERN, Pa., May 12, 2023 (GLOBE NEWSWIRE) — Baudax Bio, Inc. (Nasdaq:BXRX) (the “Company”), a pharmaceutical company focused on innovative products for hospital and related settings, today reported financial results for the quarter ended March 31, 2023, and provided a business update. “During the first quarter we made significant progress advancing our neuromuscular blocking agent (NMB) portfolio, announcing positive topline results from our Phase...

OXFORD, United Kingdom, May 12, 2023 (GLOBE NEWSWIRE) — Vaccitech plc (NASDAQ: VACC) (the Company, we or us), a clinical-stage biopharmaceutical company engaged in the discovery and development of novel immunotherapeutics and vaccines for the treatment and prevention of infectious diseases, autoimmunity and cancer, today announced its financial results for the first quarter of 2023 and an overview of the Company’s progress. “2023 has kicked off strongly for Vaccitech. In the first quarter, we strengthened our leadership team with the addition of Dr. Nadège Pelletier as our new Chief Scientific Officer, we generated positive final proof of concept data from one of our hepatitis B (HBV) trials, and very promising interim data from our human papillomavirus (HPV) program – both disease areas of high unmet medical need,” said Bill Enright,...

ANN ARBOR, Mich., May 12, 2023 (GLOBE NEWSWIRE) — Home Point Capital Inc. (NASDAQ: HMPT) (together with its subsidiaries, “Home Point Capital” or the “Company”), the parent entity of Home Point Financial Corporation (“Homepoint”), today announced its financial results for the first quarter ended March 31, 2023. In addition, as previously disclosed during the second quarter of 2023, the Company has announced the following two strategic transactions:On May 10, 2023, the Company announced the signing of a definitive agreement (the “Merger Agreement”) that provides for a wholly owned subsidiary of Mr. Cooper Group Inc. (“Mr. Cooper”) to commence a tender offer (the “Offer”) to acquire all outstanding shares of Home Point Capital for $324 million in cash (the “Merger”). As part of the transaction, Mr. Cooper will assume $500 million...

Demonstrates Strong Revenue Growth Despite Challenging e-Commerce Environment Provides Full Year 2023 Revenue and Net Income Guidance REDMOND, Wash., May 12, 2023 (GLOBE NEWSWIRE) — Hour Loop, Inc. (NASDAQ: HOUR) (“Hour Loop”), a leading online retailer, announces its financial and operational results for the quarter ended March 31, 2023. Financial Highlights for First Quarter 2023:Net revenues increased 70.5% to $21.1 million, compared to $12.4 million in the year-ago period; Net loss totaled $1.2 million, compared to net income of $0.6 million in the year-ago period; and Cash used for operating activities was $3.1 million, compared to $7.9 million in the year-ago period.Management Commentary “We are pleased to report our first quarter 2023 results, in which we delivered great performance in terms of revenue growth,” said...

Trudhesa® Achieved nTRx of Over 18.5K in Q1 2023; Increase of 112% vs. Q1 2022 Trudhesa Net Product Revenue in Q1 2023 Increased 149% vs. Q1 2022 to $4.4 Million Impel to Host Investor Conference Call Today at 8:30 a.m. ET SEATTLE, May 12, 2023 (GLOBE NEWSWIRE) — Impel Pharmaceuticals Inc. (NASDAQ: IMPL), a commercial-stage biopharmaceutical company with a mission to develop transformative therapies for people suffering from diseases with high unmet medical needs, today reported financial results for the first quarter ended March 31, 2023 and provided a business update. “Following our strategic reprioritization to focus the company on maximizing the growth potential of Trudhesa®, we are pleased with the significant increases in reimbursed prescriptions and new patient starts over the first quarter of 2023,” said Adrian Adams, Chairman...

– Received approvals to place upgraded equipment in Ecuador & at new Cancer Center JV in Mexico; Start up for both systems expected in Q3 2023 – –Announces 2nd Order of 2023 and New CFO Robert Hiatt– -Conference Call Friday May 12th at 12:00pm ET / 9:00am PT- SAN FRANCISCO, CA, May 12, 2023 (GLOBE NEWSWIRE) — via NewMediaWire – American Shared Hospital Services (NYSE American: AMS) (the “Company”), a leading provider of turnkey technology solutions for stereotactic radiosurgery and advanced radiation therapy equipment and services, today announced financial results for the first quarter ended March 31, 2023. First Quarter 2023 HighlightsTotal revenue in the first quarter was $4,925,000, an increase of 1.6% from the comparable period in 2022. Total proton therapy revenue increased...

OREM, Utah, May 12, 2023 (GLOBE NEWSWIRE) — Reflect Scientific, Inc. (OTCQB: RSCF), a provider of diverse products and services for the biotechnology, pharmaceutical, and transportation industries today reported financial results for the first quarter ended March 31, 2023. Revenues decreased by $512,449, or 68.0%, to $241,127 for the three months ended March 31, 2023 from $753,576 for the three months ended March 31, 2022. The decrease was primarily due to a significant reduction in freezer and chiller sales and ongoing supply chain delays with manufacturers. Reflect Scientific has been able to manage its expenses effectively, with salaries and wages decreasing by $8,004, or 4.7%, to $162,275 for the three months ended March 31, 2023 from $170,279 for the three months ended March 31, 2022. General and administrative expenses decreased...

Presented positive INB-100 data showing long-term complete remissions (CR) and elevated gamma-delta T cell levels in 100% of evaluable treated leukemia patients; Dose Level 2 selected as the recommended Phase 2 dose (RP2D) for the ongoing expansion with clinical updates expected in late 2023Progress across preclinical programs, including data demonstrating that gamma-delta T cells have the ability to target other solid tumors, including ovarian cancer, expanding the scope of their potential application beyond brain tumors, as well as encouraging preclinical data in the new INB-330 CAR-T program targeting acute myeloid leukemia (AML)Obtained FDA orphan drug designation (ODD) for INB-400 and INB-410, which covers a broad range of malignant gliomas, including newly diagnosed glioblastoma multiforme (GBM)Recently raised net proceeds...